Tumor protein p53 (TP53) testing and li-fraumeni syndrome: Current status of clinical applications and future directions

Molecular Diagnosis and Therapy

Volumn 17, Issue 1, 2013, Pages 31-47

  Sorrell, April D ^a   Espenschied, Carin R ^a   Culver, Julie O ^a   Weitzel, Jeffrey N ^a  

^a Division of Clinical Cancer Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P53; TAMOXIFEN; TRASTUZUMAB;

ADRENAL CORTEX CARCINOMA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMNIOCENTESIS; APLASTIC ANEMIA; AUTOPHAGY; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SCREENING; CHORION VILLUS SAMPLING; CHOROID PLEXUS TUMOR; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIGESTIVE SYSTEM CANCER; DISTRESS SYNDROME; EPENDYMOMA; ESOPHAGEAL ADENOCARCINOMA; FAMILIAL CANCER; FERTILIZATION IN VITRO; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; GLIOBLASTOMA; GLIOMA; HEAVY ION RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LUNG CANCER; MALIGNANT FIBROUS HISTIOCYTOMA; MALIGNANT TRANSFORMATION; MAMMOGRAPHY; MEDULLOBLASTOMA; MULTIMODALITY CANCER THERAPY; MUTATION RATE; MYELODYSPLASTIC SYNDROME; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY CANCER; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN TARGETING; PSYCHOLOGICAL ASPECT; PSYCHOSOCIAL CARE; RADIATION EXPOSURE; REVIEW; RISK REDUCTION; SARCOMA; SKIN CANCER; SOCIAL SUPPORT; STOMACH CANCER; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ADRENAL CORTEX NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; GENES, P53; GENETIC ASSOCIATION STUDIES; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; PEDIGREE; SARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873459266     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0020-0     Document Type: Review

References (159)

1. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li-Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27(8):1250-6.
2. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome - a molecular and clinical review. Br J Cancer. 1997;76(1):1-14.
3. Lustbader ED, Williams WR, Bondy ML, et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet. 1992;51(2):344-56.
4. Upton B, Chu Q, Li BD. Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms. Surg Oncol Clin N Am. 2009;18(1):145-56, ix.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
6. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90(8):606-11.
7. Curiel-Lewandrowski C, Speetzen LS, Cranmer L, et al. Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. Arch Dermatol. 2011;147(2):248-50.
8. Izawa N, Matsumoto S, Manabe J, et al. A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the p53 tumor-suppressor gene. Int J Clin Oncol/Jpn Soc Clin Oncol. 2008;13(1):78-82.
9. Strong LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst. 1987;79(6):1213-20.
10. Hwang SJ, Lozano G, Amos CI, et al. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003;72(4):975-83.
11. Talwalkar SS, Yin CC, Naeem RC, et al. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch Pathol Lab Med. 2010;134(7):1010-5.
12. Henry E, Villalobos V, Million L, et al. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Canc Netw. 2012;10(8):939-42.
13. Kress M, May E, Cassingena R, et al. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol. 1979;31(2):472-83.
14. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979;278(5701):261-3.
15. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979;17(1):43-52.
16. Soussi T. The history of p53. A perfect example of the drawbacks of scientific paradigms. EMBO Reports. 2010;11(11):822-6.
17. Diller L, Kassel J, Nelson CE, et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol. 1990;10(11):5772-81.
18. Baker SJ, Markowitz S, Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249(4971):912-5.
19. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453-6.
20. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15-6.
21. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-9.
22. Tabori U, Baskin B, Shago M, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010;28(8):1345-50.
23. Olivier M, Langerod A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12(4):1157-67.
24. Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, et al. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res. 2012;14(3):R70.
25. Linzer DI, Maltzman W, Levine AJ. The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology. 1979;98(2):308-18.
26. DeLeo AB, Jay G, Appella E, et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA. 1979;76(5):2420-4.
27. Crawford L. The 53,000-dalton cellular protein and its role in transformation. Int Rev Exp Pathol. 1983;25:1-50.
28. Crawford LV, Pim DC, Gurney EG, et al. Detection of a common feature in several human tumor cell lines - a 53,000-dalton protein. Proc Natl Acad Sci USA. 1981;78(1):41-5.
29. Crawford LV, Pim DC, Lamb P. The cellular protein p53 in human tumours. Mol Biol Med. 1984;2(4):261-72.
30. Koeffler HP, Miller C, Nicolson MA, et al. Increased expression of p53 protein in human leukemia cells. Proc Natl Acad Sci USA. 1986;83(11):4035-9.
31. Lubbert M, Miller CW, Crawford L, et al. p53 in chronic myelogenous leukemia: study of mechanisms of differential expression. J Exp Med. 1988;167(3):873-86.
32. Masuda H, Miller C, Koeffler HP, et al. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA. 1987;84(21):7716-9.
33. Smith LJ, McCulloch EA, Benchimol S. Expression of the p53 oncogene in acute myeloblastic leukemia. J Exp Med. 1986;164(3):751-61.
34. Lavigueur A, Maltby V, Mock D, et al. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol. 1989;9(9):3982-91.
35. Denissenko MF, Pao A, Tang M, et al. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 1996;274(5286):430-2.
36. Hainaut P, Pfeifer GP. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis. 2001;22(3):367-74.
37. Besaratinia A, Pfeifer GP. Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. FASEB J. 2010;24(8):2612-9.
38. Harvey M, McArthur MJ, Montgomery CA Jr, et al. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 1993;7(10):938-43.
39. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-21.
40. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4(1):1-7.
41. Vogelstein B. Cancer. A deadly inheritance. Nature. 1990;348(6303):681-2.
42. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst. 1969;43(6):1365-73.
43. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48(18):5358-62.
44. Lynch HT, Mulcahy GM, Harris RE, et al. Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma. Cancer. 1978;41(5):2055-64.
45. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-7.
46. Srivastava S, Zou ZQ, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348(6303):747-9.
47. Borresen AL, Andersen TI, Garber J, et al. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res. 1992;52:3234-6.
48. Birch JM. Germline mutations in the p53 tumour suppressor gene: scientific, clinical and ethical challenges. Br J Cancer. 1992;66(3):424-6.
49. Law JC, Strong LC, Chidambaram A, et al. A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res. 1991;51(23 Pt 1):6385-7.
50. Strong LC, Williams WR, Tainsky MA. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol. 1992;135(2):190-9.
51. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643-50.
52. Garritano S, Gemignani F, Palmero EI, et al. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat. 2010;31(2):143-50.
53. Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82(12):1932-7.
54. Evans DG, Birch JM, Thorneycroft M, et al. Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J Med Genet. 2002;39(12):941-4.
55. Lee DS, Yoon SY, Looi LM, et al. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res. 2012;14(2):R61.
56. Masciari S, Dillon DA, Rath M, et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni Syndrome Consortium effort. Breast Cancer Res Treat. 2012;133(3):1125-30.
57. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012;118(4):908-13.
58. Wilson JR, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet. 2010;47(11):771-4.
59. Ognjanovic S, Oliver M, Bergemann TL, et al. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer. 2012;118(5):1387-96.
60. Palmero EI, Achatz MIW, Ashton-Prolla P, et al. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol. 2010;22(1):64-9.
61. Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010;47(6):421-8.
62. Farrell CJ, Plotkin SR. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol Clin. 2007;25(4):925-46, viii.
63. Krutilkova V, Trkova M, Fleitz J, et al. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer. 2005;41(11):1597-603.
64. Garber JE, Burke EM, Lavally BL, et al. Choroid plexus tumors in the breast cancer-sarcoma syndrome. Cancer. 1990;66(12):2658-60.
65. Gozali AE, Britt B, Shane L, et al. Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer. 2012;58(6):905-9.
66. Herrmann LJ, Heinze B, Fassnacht M, et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97(3):E476-85.
67. Palmero EI, Schuler-Faccini L, Caleffi M, et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 2008;261(1):21-5.
68. Achatz MIW, Hainaut P, Ashton-Prolla P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol. 2009;10(9):920-5.
69. Pinto EM, Billerbeck AE, Villares MC, et al. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq Bras Endocrinol Metabol. 2004;48(5):647-50.
70. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA. 2001;98(16):9330-5.
71. Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2001;86(10):4970-3.
72. Figueiredo BC, Sandrini R, Zambetti GP, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet. 2006;43(1):91-6.
73. Achatz MI, Olivier M, Le Calvez F, et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 2007;245(1-2):96-102.
74. Assumpcao JG, Seidinger AL, Mastellaro MJ, et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer. 2008;8:357.
75. Wong P, Verselis SJ, Garber JE, et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology. 2006;130(1):73-9.
76. Masciari S, Dewanwala A, Stoffel EM, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med. 2011;13(7):651-7.
77. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108(44):18032-7.
78. Sui X, Jin L, Huang X, et al. p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment. Autophagy. 2011;7(6):565-71.
79. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000;60(24):6788-93.
80. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009;9(10):701-13.
81. Malkin D. Li-Fraumeni syndrome. Genes Cancer. 2011;2(4):475-84.
82. Varley J, McGown G, Thorncroft M, et al. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet. 1999;65:995-1006.
83. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54(5):1298-304.
84. Bougeard G, Sesboue R, Baert-Desurmont S, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet. 2008;45(8):535-8.
85. Andreotti V, Ciribilli Y, Monti P, et al. p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system. PloS One. 2011;6(6):e20643.
86. Horgan AM, Yang B, Azad AK, et al. Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol. 2011;6(2):296-304.
87. University of Washington. GeneTests. http://www.genetests.org. Accessed 19 July 2012.
88. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian. Version 1, 2012. http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening. pdf. Accessed 1 June 2012.
89. Eeles RA. Germline mutations in the TP53 gene. Cancer Surv. 1995;25:101-24.
90. Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001;38(1):43-7.
91. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009;27(26):e108-9. author reply e110.
92. McCuaig JM, Armel SR, Novokmet A, et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer. 2012;11(4):607-13.
93. Gonzalez KD, Buzin CH, Noltner KA, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 2009;46(10):689-93.
94. Evans D, Lunt P, Clancy T, et al. Childhood predictive genetic testing for Li-Fraumeni syndrome. Fam Cancer. 2010;9(1):65-9.
95. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011;12(6):559-67.
96. Rechitsky S, Verlinsky O, Chistokhina A, et al. Preimplantation genetic diagnosis for cancer predisposition. Reprod Biomed Online. 2002;5(2):148-55.
97. Offit K, Sagi M, Hurley K. Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. JAMA. 2006;296(22):2727-30.
98. Verlinsky Y, Rechitsky S, Verlinsky O, et al. Preimplantation diagnosis for p53 tumour suppressor gene mutations. Reprod Biomed Online. 2001;2(2):102-5.
99. Avigad S, Peleg D, Barel D, et al. Prenatal diagnosis in Li-Fraumeni syndrome. J Pediatr Hematol Oncol. 2004;26(9):541-5.
100. Peterson SK, Pentz RD, Marani SK, et al. Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome. Psychooncology. 2008;17(8):783-9.
101. Lammens CR, Aaronson NK, Wagner A, et al. Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol. 2010;28(18):3008-14.
102. Lammens CR, Bleiker EM, Verhoef S, et al. Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes. Psychooncology. 2011;20(6):631-8.
103. Storm C, Agarwal R, Offit K. Ethical and legal implications of cancer genetic testing: do physicians have a duty to warn patients' relatives about possible genetic risks? J Oncol Pract. 2008;4(5):229-30.
104. Schwarzbraun T, Obenauf AC, Langmann A, et al. Predictive diagnosis of the cancer prone Li-Fraumeni syndrome by accident: new challenges through whole genome array testing. J Med Genet. 2009;46(5):341-4.
105. Link DC, Schuettpelz LG, Shen D, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA. 2011;305(15):1568-76.
106. Engstrom PF, Bloom MG, Demetri GD, et al. NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement. J Natl Compr Cancer Netw. 2011;9(Suppl 6):S1-16.
107. NCCN panel calls for higher standards, better ways of translating molecular genetics into clinical practice. J Natl Compr Canc Netw. 2011;9(4):xliii.
108. McClure JS. Informing patients: translating the NCCN guidelines. J Natl Compr Cancer Netw. 2011;9(Suppl 3):S4-5.
109. Netzer C, Klein C, Kohlhase J, et al. New challenges for informed consent through whole genome array testing. J Med Genet. 2009;46(7):495-6.
110. Lehman CD, Smith RA. The role of MRI in breast cancer screening. J Natl Compr Cancer Netw. 2009;7(10):1109-15.
111. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89.
112. Schneider K, Garber J. Li-Fraumeni syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews. Seattle: University of Washington; 1993.
113. Masciari S, Van den Abbeele AD, Diller LR, et al. F18-fluorodeoxyglucose- positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008;299(11):1315-9.
114. Monsalve J, Kapur J, Malkin D, et al. Imaging of cancer predisposition syndromes in children. Radiographics. 2011;31(1):263-80.
115. Shlien A, Tabori U, Marshall CR, et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci USA. 2008;105(32):11264-9.
116. Tabori U, Dome JS. Telomere biology of pediatric cancer. Cancer Invest. 2007;25(3):197-208.
117. Tabori U, Nanda S, Druker H, et al. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res. 2007;67(4):1415-8.
118. Ma L, Fishell E, Wright B, et al. Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst. 1992;84(10):781-5.
119. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427-37.
120. Boyd NF, Dite GS, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med. 2002;347(12):886-94.
121. Boyd NF, Jensen HM, Cooke G, et al. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst. 1992;84(15):1170-9.
122. Weitzel JN, Buys SS, Sherman WH, et al. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res. 2007;13(2 Pt 1):654-8.
123. Mai PL, Malkin D, Garber JE, et al. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet. 2012;205(10):479-87.
124. Berrak SG, Liu DD, Wrede B, et al. Which therapy works better in choroid plexus carcinomas? J Neurooncol. 2011;103(1):155-62.
125. Tabori U, Shlien A, Baskin B, et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol. 2010;28(12):1995-2001.
126. Barton VN, Donson AM, Kleinschmidt-DeMasters BK, et al. PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer. 2009;53(7):1227-30.
127. Zenz T, Mertens D, Dohner H, et al. Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications. Leuk Lymphoma. 2008;49(5):864-73.
128. Veliz M, Pinilla-Ibarz J. Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control. 2012;19(1):37-53.
129. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43(9):1755-62.
130. Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007;48(10):1931-9.
131. Dearden CE, Richards S, Else M, et al. A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial. Cancer. 2010;117(11):2452-60.
132. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012;26(7):1458-61.
133. Hallden G, Portella G. Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opin Ther Targets. 2012;16(10):945-58.
134. Sakai R, Kagawa S, Yamasaki Y, et al. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. Mol Cancer Ther. 2010;9(6):1884-93.
135. Brower V. Cancer gene therapy steadily advances. J Natl Cancer Inst. 2008;100(18):1276-8.
136. Bishop MR, Iversen PL, Bayever E, et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol. 1996;14(4):1320-6.
137. Bishop MR, Jackson JD, Tarantolo SR, et al. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J Hematother. 1997;6(5):441-6.
138. Bang YJ. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol. 2012;46(8):637-48.
139. Jankowitz RC, Brufsky AM. Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term. Breast Cancer Res. 2012;14(2):308.
140. Hayashi M, Okumura Y, Osako T, et al. Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer. Int J Clin Oncol/Jpn Soc Clin Oncol. 2011;16(6):694-700.
141. Sachdev JC, Jahanzeb M. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin Breast Cancer. 2012;12(1):19-29.
142. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656-60.
143. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127(7):1323-34.
144. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445(7128):661-5.
145. Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol. 2011;2011:978312.
146. Bykov VJ, Issaeva N, Selivanova G, et al. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis. 2002;23(12):2011-8.
147. Rippin TM, Bykov VJ, Freund SM, et al. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene. 2002;21(14):2119-29.
148. Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. J Clin Oncol. 2012;30(29):3648-50.
149. Lehmann S, Bykov VJ, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012;30(29):3633-9.
150. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16(6):2221-32.
151. Bertheau P, Espie M, Turpin E, et al. TP53 status and response to chemotherapy in breast cancer. Pathobiology. 2008;75(2):132-9.
152. Chaiteerakij R, Yang JD, Harmsen WS, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology. Epub 2012 Oct 11.
153. Skinner HD, McCurdy MR, Echeverria AE, et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. Epub 2012 Sep 5.
154. Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. 2012;135(3):821-30.
155. Lee JH, Jeon SM, Hong SP, et al. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Digest Liver Dis. 2012;44(12):1042-7.
156. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67(14):6745-52.
157. Hamada N, Imaoka T, Masunaga S, et al. Recent advances in the biology of heavy-ion cancer therapy. J Radiat Res. 2010;51(4):365-83.
158. Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131(3):1061-6.
159. Gonzalez-Angulo AM, Broglio K, Kau SW, et al. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer. 2005;103(12):2466-72.